McKesson (MCK) Q2 2027 earnings review
McKesson raises its profit outlook, while medical-supply earnings fall
McKesson, the largest US drug distributor, grew its core pharmacy and cancer-care profits fast enough to overcome a weak medical-supply unit. Revenue rose 8% to $111 billion "due to increased prescription volumes and distribution of specialty products, partially offset by lower contributions from branded pharmaceuticals". Profit per share excluding one-offs climbed 18%, beating the pace its prior plan pointed to, and chief executive Brian Tyler raised the full-year profit outlook by $1.40 per share.
| Revenue (excluding sold European unit) | $111.0B +7.9% from a year ago by our math (+8% reported) |
|---|---|
| Profit per share, excluding one-offs | $11.68 +18% from a year ago |
| Free cash flow | $2.95B +33% from a year ago by our math |
| Full-year profit per share outlook | Raised $1.40 middle of the range: $46.00 (+18% growth) |
⚖️ Verdict: 🟢 Bullish
The story got better because cancer-care sales grew 24% even after passing the one-year anniversary of a major clinic acquisition, while North American drug distribution profit jumped 22%. In addition, second-quarter free cash flow reached $2.9 billion, easing worries over weak cash generation. One caution: borrowed money and asset sales paid for $3.4 billion of first-half stock buybacks, lifting interest costs 51%, while Medical-Surgical profit fell 10% ahead of its planned spin-off.
The question now is how much of this profit momentum comes from repeatable clinic and pharmacy demand versus front-loaded stock buybacks and temporary generic-drug gains. By our math, the raised full-year outlook points to 16% per-share profit growth in the second half, down from 19% in the first half. Third-quarter share repurchases and segment profit margins will settle whether underlying earnings can carry the load as buybacks slow.
🐂 Bull Case
Specialty Drug Distribution Lifted Core Pharma Profit 22%
North American Pharmaceutical is McKesson's largest unit, delivering drugs to pharmacies and hospital networks. Three months ago, the full-year outlook pointed by our math to roughly 7% profit growth in this unit for the rest of the year. Instead, segment profit excluding one-offs jumped 22% from a year ago to $1.04 billion, and its profit margin widened by 0.16 percentage points to 1.14%.
The drug distributor earned more because hospitals and major chains bought higher volumes of complex specialty medicines. Across the whole company, selling and administrative costs — warehouse, delivery and office overhead — rose 8% excluding one-offs while gross profit rose 10%. That gap cut overhead as a share of gross profit by 1.4 percentage points and proved that the first quarter's outlook was cautious.
What to watch: whether management raises the full-year pharmaceutical profit target on the conference call. Holding the old 5.5% to 9.5% target after a 21% first-half gain would mean management still expects second-half drug pricing or investment spending to bite.
Oncology Sales Grew 24% Past the Acquisition Anniversary
Oncology & Multispecialty — which supplies cancer clinics, manages doctor practices and runs clinical trials — is the main growth engine for the healthcare group. This quarter was the first full three-month period comparing against results that already included last year's Core Ventures cancer-clinic acquisition. Even with that tougher comparison, segment revenue rose 24.4% to $15.0 billion, well above the 14.5% to 18.5% full-year target.
Reported segment profit excluding one-offs grew only 7.6% to $427 million, and the segment margin fell 0.45 percentage points to 2.85%. That slowdown is an accounting quirk because last year's second quarter included a $51 million investment gain inside The US Oncology Network. Strip out that one-time gain, and segment profit grew about 23% by our math, matching the top-line pace.
What to watch: the underlying growth rate excluding newly acquired clinics, which finance chief Kenny Cheung usually gives on the call. A reading near 20% would show that existing cancer clinics are still expanding fast on their own.
Free Cash Flow Rebounded to $2.9 Billion in Q2
For the past two years, McKesson's free cash flow — cash from operations after capital spending — grew slower than its reported earnings. That gap narrowed sharply this quarter. The Texas-based distributor generated $2.95 billion of free cash flow in the second quarter, up 33% from a year ago by our math, lifting first-half free cash flow by 131% to $2.58 billion.
Better bill-paying terms drove the cash rebound. Over the first six months, unpaid bills to drugmakers rose by $7.8 billion while customer receivables and drug inventories absorbed $6.9 billion, creating a $915 million net cash inflow by our math. One strong quarter fades the cash-conversion concern, but we do not know yet if management raised its $4.5 billion to $4.9 billion full-year cash plan.
What to watch: the updated full-year free cash flow target in the presentation slides. A target still below last year's $5.4 billion total would mean this quarter's cash jump was just payment timing.
🐻 Bear Case
Separation Debt and Buybacks Are Driving the EPS Beat
"The raise in fiscal 2027 Adjusted Earnings per Diluted Share guidance is underpinned by the strength in our business and the confidence we have in our ability to execute consistently," finance chief Kenny Cheung said. Management treats the balance-sheet restructuring around its Medical-Surgical spin-off as a way to unlock value, yet those financial transactions carry a large part of the per-share profit growth.
- Total profit vs per-share profit: net income excluding one-offs rose 11% in Q2, while profit per share rose 18% because share count fell 6.2%
- Six-month buybacks: $3.42 billion spent ($894 million in Q2 by our math), exceeding the $2.58 billion of six-month free cash flow
- New borrowing cost: interest expense excluding one-offs jumped 51% from a year ago to $103 million after $3.22 billion of new long-term debt
The healthcare group paid for those stock buybacks by borrowing money and selling a 13% stake in its Medical-Surgical unit to Apollo Funds for $1.24 billion. Because stake sales and spin-off loans do not repeat every year, per-share profit growth will have to slow toward the 11% underlying earnings pace once the $5.0 billion buyback finishes.
What to watch: third-quarter share repurchases and interest expense. A buyback figure near $800 million alongside rising interest costs would confirm that the spin-off borrowing tailwind is already peaking.
Medical-Surgical Profit Kept Falling Ahead of Its Spin-Off
McKesson is preparing to separate Medical-Surgical Solutions, which supplies exam-room gear and bandages to clinics and nursing homes, into an independent company. While segment revenue edged up 5% to $3.1 billion in the second quarter, its operating profit excluding one-offs fell 10% to $225 million, and its profit margin dropped 1.18 percentage points to 7.27%.
The company blamed the drop on "lower contributions from the ambulatory care channel due to product mix". First-half segment profit is now down 15%, making the prior full-year target of 0% to 4% profit growth hard to reach. In addition, McKesson excluded $46 million of spin-off costs and $85 million of restructuring charges — across Medical-Surgical, Prescription Technology and corporate offices — from its headline profit.
What to watch: whether management cuts the full-year Medical-Surgical profit outlook on the call. A cut would leave the spun-off business carrying new debt into its planned stock-market debut on shrinking earnings.
Risks This Release Didn't Answer
Four standing business and regulatory questions cannot be checked from the earnings release alone because McKesson reserves those details for its conference call and quarterly filing.
- GLP-1 weight-loss and diabetes drug sales: not in the release after hitting $15 billion last quarter; the CFO's call remarks will show if sequential growth held up or lost ground to direct cash-pay channels.
- Standalone doctor-practice profits: still undisclosed inside Oncology & Multispecialty, leaving investors unable to separate clinic management returns from drug distribution.
- Government drug-price rules and biosimilar competition: the release gives no dollar estimate for upcoming Medicare Part B price caps or lower-priced cancer biosimilars.
- Retail pharmacy concentration: the Rite Aid bankruptcy charge has now passed, and McKesson extended its distribution contract with CVS Health through June 2032, easing near-term customer default risk.
👓 Other Themes
McKesson Commits $1.4 Billion to Home Infusion and Clinical Trials
After the quarter closed, chief executive Brian Tyler announced three deals to expand outside standard drug wholesaling. On October 5, McKesson agreed to pay about $1.4 billion for a 49% stake in Option Care Health, a deal aimed at "supporting the delivery of complex specialty therapies and expanding patient access through community-based care". On November 2, it bought clinical-research firm Precision Medicine Group and added 150 eye doctors to PRISM Vision.
💲 Other KPIs
Profit in Prescription Technology Solutions — software that helps pharmacies check insurance coverage and get drug approvals — rose 17.6% from a year ago, up from 12.6% growth last quarter. Segment revenue grew 10.5% to $1.52 billion on "higher demand for access solutions", lifting its profit margin by 1.23 percentage points to 20.2%.
Net debt — total debt of $9.21 billion minus $6.53 billion of cash — dropped from $4.57 billion in the first quarter as strong second-quarter operating cash flow replenished the bank balance. Compared with March 31, total debt is still up $2.68 billion, and outside investors' redeemable stakes on the balance sheet rose from $943 million to $2.56 billion.
🔮 Guidance
Raised. Management lifted the middle of the full-year range by $1.40, to $46.00, calling for 17% to 19% growth after a $0.40 raise last quarter. After $21.59 in the first half (up 19%), the new plan leaves $24.41 for the second half by our math, or about 16% growth against last year's second half as share-count reductions and generics gains slow.
❓ Key Questions
Did McKesson raise its full-year free cash flow target?
First-half free cash flow more than doubled to $2.58 billion, yet the earnings release only updated the profit per share outlook. Investors need to know if the $4.5 billion to $4.9 billion cash target moved up or if working-capital gains will reverse.
What were GLP-1 drug sales and direct-channel trends in Q2?
GLP-1 weight-loss and diabetes medications reached $15 billion of quarterly sales in Q1. Because the release omits the figure, the call must clarify whether volumes kept rising and whether drugmakers' direct cash-pay programs reduced software fee income.
How will Option Care and Precision Medicine affect debt and buybacks?
In October and November, McKesson committed $1.4 billion for a 49% stake in Option Care Health and closed the Precision Medicine Group purchase. Management has not disclosed the price paid for Precision Medicine or whether these deals reduce second-half stock buybacks.
What are the standalone profits of the acquired doctor practices?
Oncology & Multispecialty revenue grew 24% and McKesson just added 150 eye doctors to PRISM Vision. Management still combines lower-margin drug distribution with higher-margin clinic management, hiding the true return on more than $3.4 billion of acquisitions.